Willmon Fridie Jr.

Array ( [id] => 12233206 [patent_doc_number] => 20180066069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-08 [patent_title] => 'ANTI-CD38 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/703833 [patent_app_country] => US [patent_app_date] => 2017-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 24625 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15703833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16025919 [patent_doc_number] => 10675359 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-09 [patent_title] => Enzymatic conjugation of antibodies [patent_app_type] => utility [patent_app_number] => 15/702586 [patent_app_country] => US [patent_app_date] => 2017-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 34 [patent_no_of_words] => 45890 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 199 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15702586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14896999 [patent_doc_number] => 20190292265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => Methods of Treating Crohn's Disease with an Anti-NKG2D Antibody [patent_app_type] => utility [patent_app_number] => 16/325969 [patent_app_country] => US [patent_app_date] => 2017-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42246 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16325969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12177490 [patent_doc_number] => 20180036425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE' [patent_app_type] => utility [patent_app_number] => 15/678013 [patent_app_country] => US [patent_app_date] => 2017-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 70202 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15678013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12185699 [patent_doc_number] => 20180044635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-15 [patent_title] => 'SURFACE-MODIFIED MACROPHAGES FOR CELL-BASED DELIVERY' [patent_app_type] => utility [patent_app_number] => 15/674085 [patent_app_country] => US [patent_app_date] => 2017-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 7482 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15674085 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14403925 [patent_doc_number] => 20190167806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES [patent_app_type] => utility [patent_app_number] => 16/324198 [patent_app_country] => US [patent_app_date] => 2017-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -129 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16324198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12058673 [patent_doc_number] => 20170335016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'STABLE MULTIVALENT ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/670177 [patent_app_country] => US [patent_app_date] => 2017-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 28137 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15670177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12058652 [patent_doc_number] => 20170334996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'FUSION PROTEINS CONTAINING RECOMBINANT CYTOTOXIC RNASES' [patent_app_type] => utility [patent_app_number] => 15/666902 [patent_app_country] => US [patent_app_date] => 2017-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 12171 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15666902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15538433 [patent_doc_number] => 10568977 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-25 [patent_title] => Antibodies that bind activatable antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/660215 [patent_app_country] => US [patent_app_date] => 2017-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 29206 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 243 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15660215 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268871 [patent_doc_number] => 20200270358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => AFUCOSYLATED MONOCLONAL ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/345648 [patent_app_country] => US [patent_app_date] => 2017-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3251 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16345648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14464715 [patent_doc_number] => 20190183997 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => IDENTIFICATION AND PRODUCTION OF HIGH AFFINITY IGM ANTIBODIES AND DERIVATIVES THEREOF [patent_app_type] => utility [patent_app_number] => 16/319755 [patent_app_country] => US [patent_app_date] => 2017-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43833 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16319755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17378146 [patent_doc_number] => 11236143 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Extracellular vesicle comprising a fusion protein having Fc binding capacity [patent_app_type] => utility [patent_app_number] => 16/319061 [patent_app_country] => US [patent_app_date] => 2017-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 18557 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16319061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14963219 [patent_doc_number] => 20190309087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => MODULAR PLATFORM FOR TARGETED THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 16/316629 [patent_app_country] => US [patent_app_date] => 2017-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20821 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16316629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15023503 [patent_doc_number] => 20190322756 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => METHODS AND MATERIALS FOR ASSESSING RESPONSE TO PLASMABLAST- AND PLASMA CELL-DEPLETING THERAPIES [patent_app_type] => utility [patent_app_number] => 16/317606 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28851 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16317606 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15228123 [patent_doc_number] => 10501775 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-10 [patent_title] => Antigen binding molecules and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/646817 [patent_app_country] => US [patent_app_date] => 2017-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 17 [patent_no_of_words] => 44648 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15646817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16533344 [patent_doc_number] => 10875928 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-29 [patent_title] => IgM and IgE heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity [patent_app_type] => utility [patent_app_number] => 15/645892 [patent_app_country] => US [patent_app_date] => 2017-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 45 [patent_no_of_words] => 21609 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15645892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14685527 [patent_doc_number] => 20190241878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => OPTIMIZED BINUCLEASE FUSIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/313656 [patent_app_country] => US [patent_app_date] => 2017-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26831 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16313656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15227695 [patent_doc_number] => 10501558 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-10 [patent_title] => Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use [patent_app_type] => utility [patent_app_number] => 15/632196 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 23 [patent_no_of_words] => 57824 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15632196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15978077 [patent_doc_number] => 10669347 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-02 [patent_title] => Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use [patent_app_type] => utility [patent_app_number] => 15/632192 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 20 [patent_no_of_words] => 61628 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15632192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13702737 [patent_doc_number] => 20170362323 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => HETERODIMER PROTEIN COMPOSITION [patent_app_type] => utility [patent_app_number] => 15/624581 [patent_app_country] => US [patent_app_date] => 2017-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31368 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15624581 [rel_patent_id] =>[rel_patent_doc_number] =>)